| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 411.2 | 402.1 |
| Profit before tax | 15.7 | -6.8 |
| Net income | 14.9 | -5.4 |
| EPS (diluted, $ a share) | $0.19 | $-0.07 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +2.3% |
|---|---|
| Operating margin | 4.6% |
10-Q filed with the SEC, NASDAQ: IART. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Integra Lifesciences Holdings Corp: key numbers
- Share price
- $13.55Close, Nov 17
- Market cap
- $1.05B
- Shares outstanding
- 77.8MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Integra Lifesciences Holdings Corp
All →Integra Lifesciences Holdings Financial Results
Integra LifeSciences reported Q3 2026 revenues of $411.2 million, a 2.3% increase year-over-year, despite a $7 million impact from flood damage at its Cincinnati facility. The company achieved GAAP net income of $14.9 million ($0.19 per share) and adjusted EPS of $0.59, while generating $96 million in operating cash flow.
- Term
- Q3 2026
“Our third quarter performance reflected mixed results across our portfolio, with stronger performance in Specialty Surgery partially offset by a $7 million impact from the Cincinnati disruption and softer-than-expected results in Tissue Reconstruction. We delivered results within our guidance ranges, generated strong cash flow, reduced leverage, and subsequently completed our debt refinancing.”
Stuart Essig, Chairman and Chief Executive Officer
“Our updated outlook reflects both the recovery timeline in Cincinnati and more measured expectations for portions of our Tissue Reconstruction business. We are focused on executing against these challenges while continuing to support our customers, advance key product launches and returns, and strengthen the business for more consistent long-term growth.”
Stuart Essig, Chairman and Chief Executive Officer
Integra Lifesciences Holdings $1.65B Debt Financing with Bank of America, N.A.
Integra LifeSciences completed a comprehensive refinancing of its debt, entering into a new $1.65 billion amended and restated credit agreement and issuing $450 million in 9.500% senior secured notes due 2033. The credit facility includes a $600 million revolver, a $600 million Term Loan A, and a $450 million Term Loan B. Proceeds were used to refinance the company's existing credit facility and pay related fees.
- Value
- $1.65B
- Counterparty
- Bank of America, N.A.
- Term
- 5-7 years
Integra Lifesciences Holdings $450M Debt Financing
Integra LifeSciences announced the pricing of $450 million in 9.500% senior secured notes due 2033 in a private placement. The company intends to use the proceeds, along with a new credit facility, to refinance its existing debt obligations. Management noted that this refinancing is expected to increase the company's effective interest rate by approximately 100-200 basis points.
- Value
- $450M
- Term
- 9 years
Integra Lifesciences Holdings Business Update
Integra LifeSciences announced preliminary Q3 2026 revenue of $410-$412 million and updated its full-year guidance to reflect a $22-$27 million total revenue impact from flooding at its Cincinnati manufacturing facility. The company expects the facility to return to full operations in Q2 2027 and anticipates insurance recoveries to mitigate a substantial portion of the financial impact.